IP Library Patent Application 11170762
Patent Application
App. No. 11/170,762

DNA polymerase blends and mutant DNA polymerases

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/170,762
Abstract

A thermostable DNA polymerase composition comprising at least two DNA polymerases, one of which is substantially reduced in 5′-exonuclease activity and one of which has 5′-exonuclease activity. This polymerase may be used in methods including, but not limited to, nucleic acid synthesis, DNA sequencing, nucleic acid amplification and cDNA synthesis,

Claims (31)

1 . An isolated recombinant nucleic acid molecule encoding a Thermus filiformis (Tfi) DNA polymerase having a D144A point mutation, wherein said point mutation substantially reduces the 5′-exonuclease activity of said polymerase.

2 . The isolated nucleic acid molecule of claim 1 , further comprising an E437D point mutation.

3 . An isolated mutant Tfi DNA polymerase produced from the nucleic acid molecule of claim 1 .

4 . An isolated mutant Tfi DNA polymerase having a D144A point mutation.

5 . An isolated mutant Tfi DNA polymerase having D144A and E437D point mutations.

6 . A composition comprising at least two thermostable DNA polymerases wherein at least one of said polymerases is substantially reduced in 5′ exonuclease activity (exo−) and wherein at least one of said polymerases has 5′ exonuclease activity (exo+).

7 . The composition of claim 6 , wherein said polymerases are from the same species of thermophilic bacteria.

8 . The composition of claim 6 , wherein said 5′-exo− and said 5′-exo+ polymerases are combined in a ratio of between 9:1 and 1:9 (exo−:exo+).

9 . The composition of claim 8 , wherein the ratio is 7:3 (exo−:exo+)

10 . A vector comprising the isolated nucleic acid molecule of claim 1 .

11 . The vector of claim 10 wherein said nucleic acid molecule is operably linked to a promoter.

12 . A host cell comprising the vector of claim 11 .

13 . The composition of claim 6 , further comprising at least two components selected from the group consisting of a detergent, buffer salt, deoxynucleoside triphosphate (dNTP) and dideoxynucleoside triphosphate (dNTP).

14 . The composition of claim 13 , wherein said components are a detergent, buffer salt and dNTP.

15 . A method of synthesizing a double-stranded DNA molecule, comprising:

(a) hybridizing a primer to a first DNA molecule; and

(b) incubating said DNA molecule recited in (a) in the presence of one or more deoxy- or didexoyribonucleoside triphosphates and the composition of claim 6 under conditions sufficient to synthesize a second DNA molecule complementary to all or a portion of said first DNA molecule.

16 . A method of amplifying a double stranded DNA molecule, comprising:

(a) providing a first and second primer, wherein said first primer is complementary to a sequence at or near the 3′-terminus of the first strand of said DNA molecule and said second primer is complementary to a sequence at or near the 3′-terminus of the second strand of said DNA molecule;

(b) hybridizing said first primer to said first strand and said second primer to said second strand in the presence of the composition of claim 6 , under conditions such that the third strand complementary to said first strand and a fourth strand complementary to said second strand are synthesized;

(c) denaturing said first and third strands and said second and fourth strands; and

(d) repeating steps (a) to (c) one or more times.

17 . (canceled)

18 . (canceled)

19 . A method of preparing cDNA from mRNA, comprising:

(a) contacting mRNA with an oligo(dT) primer or other complementary primer to form a hybrid; and

(b) contacting said hybrid formed in (a) with the composition of claim 6 and dATP, dCTP, dGTP and dTTP, whereby a cDNA-RNA hybrid is obtained.

20 . A method of preparing dsDNA from mRNA, comprising:

(a) contacting mRNA with an oligo(dT) primer or other complementary primer to form a hybrid; and

(b) contacting said hybrid formed in (a) with the composition of claim 6 , dATP, dCTP, dGTP and dTTP, and an oligonucleotide or primer which is complementary to the first strand cDNA; whereby dsDNA is obtained.

21 . An isolated mutant Tfi DNA polymerase produced from the nucleic acid molecule of claim 2.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE APPLICATION NO 09452626 PREVIOUSLY RECORDED ON REEL 023882 FRAME 0551. ASSIGNOR(S) HEREBY CONFIRMS THE MERGER SHOULD NOT HAVE BEEN RECORDED AGAINST THIS PATENT APPLICATION NUMBER. Recorded Nov 14, 2014
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 034217/0490 →
MERGER Recorded Feb 3, 2010
From: INVITROGEN CORPORATION
To: LIFE TECHNOLOGIES CORPORATION
Reel/Frame 023882/0551 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 16, 2006
From: ZHENG, WEIDONG; LEE, JUN E.; POTTER, ROBERT JASON; MANDELMANN, DAVID
To: INVITROGEN CORPORATION
Reel/Frame 017349/0773 →